Core Viewpoint - The launch of the phase III clinical trial for "Huangjia Soft Liver Granules" by Weikang Pharmaceutical is a significant step towards evaluating its efficacy and safety in treating chronic hepatitis B liver fibrosis, with the potential to enhance treatment options in this area [1][2][3] Group 1: Clinical Trial Details - The phase III clinical trial aims to assess the effectiveness and safety of "Huangjia Soft Liver Granules" for chronic hepatitis B liver fibrosis, involving 19 centers including Anhui Medical University First Affiliated Hospital [1] - The trial will include 480 participants and is designed as a randomized, double-blind, placebo-controlled, multi-center study [1] - Previous phase II trial results indicated that "Huangjia Soft Liver Granules" demonstrated good efficacy and safety, with clinical benefits for patients outweighing potential risks [1] Group 2: Market Context and Company Position - There are currently only four traditional Chinese medicines undergoing clinical trials for liver fibrosis, with "Huangjia Soft Liver Granules" being one of the few advancing to phase III, indicating a leading position in this therapeutic area [2] - Weikang Pharmaceutical has established a robust research and development framework, including multiple provincial-level research centers and collaborations with notable scientists, enhancing its competitive edge in the pharmaceutical industry [2] - The company has successfully developed the "Yinhuang Diyan" product, gaining significant market recognition, and is also exploring new product lines such as "Lingzhi Spore Powder" to create a second growth curve [2] Group 3: Future Outlook - The steady progress of the phase III clinical trial for "Huangjia Soft Liver Granules" is expected to lead to breakthroughs in liver disease treatment, potentially improving the clinical management of chronic hepatitis B in China [3]